Ruotsalainen Tarja, Joensuu Heikki, Mattson Karin, Salven Petri
Department of Internal Medicine, Helsinki University Central Hospital, FIN-00290 Helsinki, Finland.
Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1492-5.
Basic fibroblast growth factor (bFGF) is a secreted multifunctional cytokine and a potent stimulator of angiogenesis. We measured bFGF concentrations from serum samples taken from 103 patients with small cell lung cancer at the time of diagnosis. Serum concentration of bFGF (S-bFGF) ranged from undetectable to 54 pg/ml (median, 6 pg/ml). S-bFGF was not associated with age, sex, performance status, or stage. A high pretreatment S-bFGF was associated with poor overall survival. The 1- and 2-year survival rates of the patients within the highest quartile of S-bFGF (>or=17 pg/ml) were only 26% and 11%, respectively, in contrast to the 49% and 20% 1- and 2-year survival rates of those patients with S-bFGF < 17 pg/ml (P = 0.013). The 1- and 2-year survival rates of the patients with extensive-stage disease were 33% and 10%, respectively (P = 0.0091). Interestingly, S-bFGF provided additional prognostic information to the stage because the 1- and 2-year survival rates of patients with extensive-stage disease and a high S-bFGF (>or=17 pg/ml) were as low as 16% and 5%, respectively (P = 0.0026). Similarly, in the multivariate model of survival analysis, patients with both extensive-stage disease and a high S-bFGF (>or=17 pg/ml) were found to have a particularly poor prognosis (relative risk of death, 2.1; 95% confidence interval, 1.2-3.6; P = 0.0057). We conclude that a high S-bFGF at diagnosis is associated with poor outcome in small cell lung cancer, possibly reflecting active angiogenesis and rapid tumor growth, and may complement prognostic information obtained by staging.
碱性成纤维细胞生长因子（bFGF）是一种分泌型多功能细胞因子，也是血管生成的强效刺激因子。我们检测了103例小细胞肺癌患者诊断时血清样本中的bFGF浓度。血清bFGF（S-bFGF）浓度范围为检测不到至54 pg/ml（中位数为6 pg/ml）。S-bFGF与年龄、性别、体能状态或分期无关。治疗前S-bFGF水平高与总生存期差相关。S-bFGF处于最高四分位数（≥17 pg/ml）的患者1年和2年生存率分别仅为26%和11%，相比之下，S-bFGF＜17 pg/ml的患者1年和2年生存率分别为49%和20%（P = 0.013）。广泛期疾病患者的1年和2年生存率分别为33%和10%（P = 0.0091）。有趣的是，S-bFGF为分期提供了额外的预后信息，因为广泛期疾病且S-bFGF水平高（≥17 pg/ml）的患者1年和2年生存率分别低至16%和5%（P = 0.0026）。同样，在生存分析的多变量模型中，发现广泛期疾病且S-bFGF水平高（≥17 pg/ml）的患者预后特别差（死亡相对风险为2.1；95%置信区间为1.2 - 3.6；P = 0.0057）。我们得出结论，诊断时高S-bFGF与小细胞肺癌的不良预后相关，可能反映了活跃的血管生成和肿瘤快速生长，并且可能补充分期所获得的预后信息。
